Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


Oxaliplatin antagonizes HIV-1 latency by activating NF-κB without causing global T cell activation.

Zhu X, Liu S, Wang P, Qu X, Wang X, Zeng H, Chen H, Zhu H.

Biochem Biophys Res Commun. 2014 Jul 18;450(1):202-7. doi: 10.1016/j.bbrc.2014.05.088.


As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB.

Wang P, Qu X, Wang X, Liu L, Zhu X, Zeng H, Zhu H.

Antiviral Res. 2013 Dec;100(3):688-97.


Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cδ-NF-κB signaling.

Jiang G, Mendes EA, Kaiser P, Sankaran-Walters S, Tang Y, Weber MG, Melcher GP, Thompson GR 3rd, Tanuri A, Pianowski LF, Wong JK, Dandekar S.

AIDS. 2014 Jul 17;28(11):1555-66. doi: 10.1097/QAD.0000000000000289.


Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.

Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, Kan TW, Boucher C, Verbon A, Dykhuizen EC, Mahmoudi T.

EBioMedicine. 2015 Nov 27;3:108-21. doi: 10.1016/j.ebiom.2015.11.047.


Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.

Wolschendorf F, Duverger A, Jones J, Wagner FH, Huff J, Benjamin WH, Saag MS, Niederweis M, Kutsch O.

J Virol. 2010 Sep;84(17):8712-20. doi: 10.1128/JVI.00523-10.


Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation.

Jiang G, Mendes EA, Kaiser P, Wong DP, Tang Y, Cai I, Fenton A, Melcher GP, Hildreth JE, Thompson GR, Wong JK, Dandekar S.

PLoS Pathog. 2015 Jul 30;11(7):e1005066. doi: 10.1371/journal.ppat.1005066.


Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Yang HC, Xing S, Shan L, O'Connell K, Dinoso J, Shen A, Zhou Y, Shrum CK, Han Y, Liu JO, Zhang H, Margolick JB, Siliciano RF.

J Clin Invest. 2009 Nov;119(11):3473-86. doi: 10.1172/JCI39199.


An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.

Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C.

PLoS Pathog. 2015 Jul 30;11(7):e1005063. doi: 10.1371/journal.ppat.1005063.


Calcium/calcineurin synergizes with prostratin to promote NF-κB dependent activation of latent HIV.

Chan JK, Bhattacharyya D, Lassen KG, Ruelas D, Greene WC.

PLoS One. 2013 Oct 30;8(10):e77749. doi: 10.1371/journal.pone.0077749.


The development of immune-modulating compounds to disrupt HIV latency.

Remoli AL, Marsili G, Battistini A, Sgarbanti M.

Cytokine Growth Factor Rev. 2012 Aug-Oct;23(4-5):159-72. doi: 10.1016/j.cytogfr.2012.05.003. Review.


As2O3 synergistically reactivate latent HIV-1 by induction of NF-κB.

Wang P, Qu X, Wang X, Liu L, Zhu X, Zeng H, Zhu H.

Antiviral Res. 2013 Oct 25. pii: S0166-3542(13)00300-8. doi: 10.1016/j.antiviral.2013.10.010. [Epub ahead of print]


Reactivation of latent HIV-1 by new semi-synthetic ingenol esters.

Pandeló José D, Bartholomeeusen K, da Cunha RD, Abreu CM, Glinski J, da Costa TB, Bacchi Rabay AF, Pianowski Filho LF, Dudycz LW, Ranga U, Peterlin BM, Pianowski LF, Tanuri A, Aguiar RS.

Virology. 2014 Aug;462-463:328-39. doi: 10.1016/j.virol.2014.05.033.


Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Wolschendorf F, Bosque A, Shishido T, Duverger A, Jones J, Planelles V, Kutsch O.

J Virol. 2012 Apr;86(8):4548-58. doi: 10.1128/JVI.06726-11.


Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation.

Yang HC, Shen L, Siliciano RF, Pomerantz JL.

Proc Natl Acad Sci U S A. 2009 Apr 14;106(15):6321-6. doi: 10.1073/pnas.0809536106.


Differential effects of phorbol-13-monoesters on human immunodeficiency virus reactivation.

Márquez N, Calzado MA, Sánchez-Duffhues G, Pérez M, Minassi A, Pagani A, Appendino G, Diaz L, Muñoz-Fernández MA, Muñoz E.

Biochem Pharmacol. 2008 Mar 15;75(6):1370-80. doi: 10.1016/j.bcp.2007.12.004.


Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus.

Hori T, Barnor J, Huu TN, Morinaga O, Hamano A, Ndzinu J, Frimpong A, Minta-Asare K, Amoa-Bosompem M, Brandful J, Odoom J, Bonney J, Tuffour I, Owusu BA, Ofosuhene M, Atchoglo P, Sakyiamah M, Adegle R, Appiah-Opong R, Ampofo W, Koram K, Nyarko A, Okine L, Edoh D, Appiah A, Uto T, Yoshinaka Y, Uota S, Shoyama Y, Yamaoka S.

Biochem Biophys Res Commun. 2015 Apr 3;459(2):288-93. doi: 10.1016/j.bbrc.2015.02.102. Erratum in: Biochem Biophys Res Commun. 2015 Jun 12;461(4):702.


Dilazep synergistically reactivates latent HIV-1 in latently infected cells.

Zeng H, Liu S, Wang P, Qu X, Ji H, Wang X, Zhu X, Song Z, Yang X, Ma Z, Zhu H.

Mol Biol Rep. 2014 Nov;41(11):7697-704. doi: 10.1007/s11033-014-3662-z.


Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Xing S, Bullen CK, Shroff NS, Shan L, Yang HC, Manucci JL, Bhat S, Zhang H, Margolick JB, Quinn TC, Margolis DM, Siliciano JD, Siliciano RF.

J Virol. 2011 Jun;85(12):6060-4. doi: 10.1128/JVI.02033-10.


Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Xing S, Bhat S, Shroff NS, Zhang H, Lopez JA, Margolick JB, Liu JO, Siliciano RF.

J Antimicrob Chemother. 2012 Feb;67(2):398-403. doi: 10.1093/jac/dkr496.


TLR5 stimulation is sufficient to trigger reactivation of latent HIV-1 provirus in T lymphoid cells and activate virus gene expression in central memory CD4+ T cells.

Thibault S, Imbeault M, Tardif MR, Tremblay MJ.

Virology. 2009 Jun 20;389(1-2):20-5. doi: 10.1016/j.virol.2009.04.019.

Items per page

Supplemental Content

Support Center